These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 9007092

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Decreased striatal monoaminergic terminals in Huntington disease.
    Bohnen NI, Koeppe RA, Meyer P, Ficaro E, Wernette K, Kilbourn MR, Kuhl DE, Frey KA, Albin RL.
    Neurology; 2000 May 09; 54(9):1753-9. PubMed ID: 10802780
    [Abstract] [Full Text] [Related]

  • 3. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease.
    Bohnen NI, Albin RL, Koeppe RA, Wernette KA, Kilbourn MR, Minoshima S, Frey KA.
    J Cereb Blood Flow Metab; 2006 Sep 09; 26(9):1198-212. PubMed ID: 16421508
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Assessment of extrastriatal vesicular monoamine transporter binding site density using stereoisomers of [11C]dihydrotetrabenazine.
    Koeppe RA, Frey KA, Kuhl DE, Kilbourn MR.
    J Cereb Blood Flow Metab; 1999 Dec 09; 19(12):1376-84. PubMed ID: 10598942
    [Abstract] [Full Text] [Related]

  • 6. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease.
    Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE, Wudel J, Pal PK, de la Fuente-Fernandez R, Calne DB, Stoessl AJ.
    Ann Neurol; 2000 Apr 09; 47(4):493-503. PubMed ID: 10762161
    [Abstract] [Full Text] [Related]

  • 7. Striatal presynaptic monoaminergic vesicles are not increased in Tourette's syndrome.
    Meyer P, Bohnen NI, Minoshima S, Koeppe RA, Wernette K, Kilbourn MR, Kuhl DE, Frey KA, Albin RL.
    Neurology; 1999 Jul 22; 53(2):371-4. PubMed ID: 10430428
    [Abstract] [Full Text] [Related]

  • 8. Kinetic evaluation of [11C]dihydrotetrabenazine by dynamic PET: measurement of vesicular monoamine transporter.
    Koeppe RA, Frey KA, Vander Borght TM, Karlamangla A, Jewett DM, Lee LC, Kilbourn MR, Kuhl DE.
    J Cereb Blood Flow Metab; 1996 Nov 22; 16(6):1288-99. PubMed ID: 8898703
    [Abstract] [Full Text] [Related]

  • 9. In vivo imaging of the brain vesicular monoamine transporter.
    Vander Borght TM, Kilbourn MR, Koeppe RA, DaSilva JN, Carey JE, Kuhl DE, Frey KA.
    J Nucl Med; 1995 Dec 22; 36(12):2252-60. PubMed ID: 8523116
    [Abstract] [Full Text] [Related]

  • 10. VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET.
    De La Fuente-Fernández R, Furtado S, Guttman M, Furukawa Y, Lee CS, Calne DB, Ruth TJ, Stoessl AJ.
    Synapse; 2003 Jul 22; 49(1):20-8. PubMed ID: 12710012
    [Abstract] [Full Text] [Related]

  • 11. In vivo measurement of the vesicular monoamine transporter in schizophrenia.
    Taylor SF, Koeppe RA, Tandon R, Zubieta JK, Frey KA.
    Neuropsychopharmacology; 2000 Dec 22; 23(6):667-75. PubMed ID: 11063922
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Decreased striatal monoaminergic terminals in severe chronic alcoholism demonstrated with (+)[11C]dihydrotetrabenazine and positron emission tomography.
    Gilman S, Koeppe RA, Adams KM, Junck L, Kluin KJ, Johnson-Greene D, Martorello S, Heumann M, Bandekar R.
    Ann Neurol; 1998 Sep 22; 44(3):326-33. PubMed ID: 9749598
    [Abstract] [Full Text] [Related]

  • 15. High vesicular monoamine transporter binding in asymptomatic bipolar I disorder: sex differences and cognitive correlates.
    Zubieta JK, Huguelet P, Ohl LE, Koeppe RA, Kilbourn MR, Carr JM, Giordani BJ, Frey KA.
    Am J Psychiatry; 2000 Oct 22; 157(10):1619-28. PubMed ID: 11007716
    [Abstract] [Full Text] [Related]

  • 16. Differentiating Alzheimer's disease from dementia with Lewy bodies and Parkinson's disease with (+)-[11C]dihydrotetrabenazine positron emission tomography.
    Koeppe RA, Gilman S, Junck L, Wernette K, Frey KA.
    Alzheimers Dement; 2008 Jan 22; 4(1 Suppl 1):S67-76. PubMed ID: 18632004
    [Abstract] [Full Text] [Related]

  • 17. Reproducibility studies with 11C-DTBZ, a monoamine vesicular transporter inhibitor in healthy human subjects.
    Chan GL, Holden JE, Stoessl AJ, Samii A, Doudet DJ, Dobko T, Morrison KS, Adam M, Schulzer M, Calne DB, Ruth TJ.
    J Nucl Med; 1999 Feb 22; 40(2):283-9. PubMed ID: 10025836
    [Abstract] [Full Text] [Related]

  • 18. Imaging the vesicular monoamine transporter.
    Frey KA, Koeppe RA, Kilbourn MR.
    Adv Neurol; 2001 Feb 22; 86():237-47. PubMed ID: 11553983
    [Abstract] [Full Text] [Related]

  • 19. Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker?
    Boileau I, Rusjan P, Houle S, Wilkins D, Tong J, Selby P, Guttman M, Saint-Cyr JA, Wilson AA, Kish SJ.
    J Neurosci; 2008 Sep 24; 28(39):9850-6. PubMed ID: 18815269
    [Abstract] [Full Text] [Related]

  • 20. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters.
    Goswami R, Ponde DE, Kung MP, Hou C, Kilbourn MR, Kung HF.
    Nucl Med Biol; 2006 Aug 24; 33(6):685-94. PubMed ID: 16934687
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.